Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JW55 |
Synonyms | |
Therapy Description |
JW55 selectively inhibits Wnt/beta-catenin-mediated signaling by inhibiting tankyrase1/2, thus stabilizing axin and stimulating beta-catenin degradation, which prevents cell division and decreases tumor growth (PMID: 22440753). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JW55 | JW 55 | Tankyrase Inhibitor 11 | JW55 selectively inhibits Wnt/beta-catenin-mediated signaling by inhibiting tankyrase1/2, thus stabilizing axin and stimulating beta-catenin degradation, which prevents cell division and decreases tumor growth (PMID: 22440753). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC inact mut | colon cancer | sensitive | JW55 | Preclinical | Actionable | In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753). | 22440753 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|